Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250). Ingham M, Allred JB, Chen L, Das B, et al. J Clin Oncol 2023;41:4154-4163.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ingham M, Allred JB, Chen L, Das B, et al. Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250). J Clin Oncol 2023;41:4154-4163.
PMID: 37467452